Abstract 1410P
Background
AGAMENON-SEOM is a registry of patients with unresectable or metastatic gastric adenocarcinoma (GC), esophageal-gastric junction (GEJC), or distal esophagus adenocarcinoma (EAC). The objectives are to describe clinical characteristics at diagnosis and progression, 1st-line treatment patterns, and to evaluate progression-free survival (PFS) and overall survival (OS). An OS analysis was also performed based on the different clinical characteristics.
Methods
3110 patients from 35 Spanish centers were included from 2010 to 2020. PFS was defined as the time from diagnosis to the date of first progression or death (PFS1) and from the start of each line of treatment (PFS2, PFS3). OS was defined as the time from the start of each of the treatment lines to death. The Kaplan-Meier test was used for survival analyzes.
Results
The mean age was 65 years (20-89), with 71% ECOG1. The most frequent tumor was GC (77%), the histological subtype, intestinal (41.7%), and 22% had HER2+ tumors (predominance in intestinal histology and grades 1-2). The most frequent metastatic location were the lymph node (46.4%), in the HER2+ subtype, it was the liver (53.8%). The most used treatments were FOLFOX (20%) and CAPOX (19%); in HER2+ CAPOX-Trastuzumab (T) (27%) and cisplatin-capecitabine-T (26%). The most used 2nd line regimens were paclitaxel (22%), pacitaxel-ramucirumab (20.6%) and docetaxel (14.2%); and in 3rd line, irinotecan (35.9%) and FOLFIRI (18.1%). With a median follow-up of 57 months (95% CI, 50.8-69.9), PFS1 was 6 (95% CI, 5.8-6.2) and OS1, 10.8 months (95% CI, 10.4-11.2). PFS2 was 3.6 (CI 95%, 3.3-4) and OS2, 5.8 months (CI 95%, 5.3-6.2). PFS3 was 3.4 (95% CI, 3.1-4.1) and OS3, 4.9 months (95% CI, 4.2-6.0). Table: 1410P
OS data according to the characteristics of the patients
| N/events | Median OS from 1L therapy (months CI 95%) | |
| All | 3037/2632 | 10.8 (10.4-11.2) |
| HER2-negative | 2346/2040 | 10.1 (9.7-10.5) |
| HER2-positive | 691/592 | 13.8 (12.7-14.7) |
| ECOG PS 0 | 710/585 | 12.6 (11.7-13.8) |
| ECOG PS 1 | 1877/1630 | 11.3 (10.7-11.9) |
| ECOG PS 2 | 432/399 | 5.9 (5.4-7.0) |
| ECOG PS 3 | 16/16 | 5.0 (3.1-14.7) |
| Intestinal | 1048/887 | 12.3 (11.6-13.2) |
| Diffuse | 960/838 | 9.53 (8.5-10.19) |
| EAC | 267/220 | 12.3 (10.9-14.0) |
| GC | 2360/2060 | 10.7 (10.2-11.1) |
| GEJC | 410/352 | 10.5 (9.7-11.6) |
Conclusions
The Spanish AGAMENON-SEOM registry includes a representative sample of patients, predominantly first-line treated with platinum and fluoropyrimidine. PFS and OS, influenced by clinical characteristics, reproduced those published in the literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
I. Macias Declara: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Invited Speaker: BMS. R. Hernandez: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Invited Speaker: Servier; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Invited Speaker: Ipsen. N. Castro Unanua: Non-Financial Interests, Personal, Training: Pfizer; Non-Financial Interests, Personal, Training: Roche; Non-Financial Interests, Personal, Training: Merck; Non-Financial Interests, Personal, Training: LeoPharma; Non-Financial Interests, Personal, Training: Sanofi. D. Cacho: Financial Interests, Personal, Invited Speaker: LeoPharma; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Sanofi. A. Fernandez Montes: Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Servier; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: Pierre Fabre; Financial Interests, Personal, Invited Speaker: Merck. M. Diez: Financial Interests, Personal, Invited Speaker: Lilly. R. Vidal Tocino: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Invited Speaker: Celgene; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Advisory Board: Sanofi; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Invited Speaker: Servier; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Invited Speaker: Roche; Non-Financial Interests, Personal, Training: Lilly; Non-Financial Interests, Personal, Training: Amgen; Non-Financial Interests, Personal, Training: BMS; Non-Financial Interests, Personal, Training: Roche; Non-Financial Interests, Personal, Training: Servier; Non-Financial Interests, Personal, Training: Sanofi. M. Mangas Izquierdo: Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Invited Speaker: Servier; Financial Interests, Personal, Invited Speaker: Celgene; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Invited Speaker: Roche. A. Carmona-Bayonas: Financial Interests, Personal, Advisory Board: Bristol; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Mylan; Financial Interests, Personal, Advisory Board: Baxter; Financial Interests, Personal, Invited Speaker: HRA Pharma; Financial Interests, Personal, Invited Speaker: LeoPharma; Financial Interests, Personal, Invited Speaker: Rovi; Financial Interests, Personal, Invited Speaker: Sanofi. P. Jimenez-Fonseca: Financial Interests, Personal, Advisory Board: Bristol; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Mylan; Financial Interests, Personal, Advisory Board: Baxter; Financial Interests, Personal, Invited Speaker: HRA Pharma; Financial Interests, Personal, Invited Speaker: Leo Pharma; Financial Interests, Personal, Invited Speaker: Rovi; Financial Interests, Personal, Invited Speaker: Sanofi. All other authors have declared no conflicts of interest.